Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease

Recruiting now · Not applicable

Conditions studied: Metabolic Dysfunction-associated Steatotic Liver Disease

In brief

Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.

Key facts

Study ID

NCT06506513

Run by

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

People needed

60

Starts

2025-09-01

Expected to finish

2027-09-01

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• confirmed MASLD at abdominal imaging
• confirmed excessive muscle lipid content at imaging
• stable weight

You may not qualify if…

• severe comorbidities including active malignancies, neuromuscular degenerative diseases
• contraindications to physical activity
• excessive alcohol consumption

Where it is running

• Cliniques universitaires Saint-Luc — Brussels, Belgium (enrolling)
• Centre d'investigation clinique en nutrition — Louvain-la-Neuve, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.